MetaVia (NASDAQ:MTVA) Posts Earnings Results, Misses Estimates By $0.08 EPS

MetaVia (NASDAQ:MTVA) posted its quarterly earnings results on Thursday. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.08), FiscalAI reports.

MetaVia Trading Up 2.8%

Shares of MTVA traded up $0.04 during trading hours on Friday, reaching $1.49. 107,022 shares of the company’s stock traded hands, compared to its average volume of 549,292. The stock has a market cap of $7.69 million, a PE ratio of -0.29 and a beta of 0.95. The firm’s 50 day simple moving average is $1.72 and its 200-day simple moving average is $1.75. MetaVia has a 12 month low of $0.97 and a 12 month high of $19.03.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new stake in shares of MetaVia Inc. (NASDAQ:MTVA) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia at the end of the most recent reporting period. 1.37% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of MetaVia in a research report on Friday, July 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a research note on Tuesday, July 21st. Finally, Wall Street Zen raised shares of MetaVia to a “sell” rating in a report on Saturday, June 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $20.00.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.